Sanofi Provides Unprecedented Access to its Insulins for One Set Monthly Price

Sanofi continues its commitment to helping reduce cost burden for people living with diabetes with first-ever insulin savings program

Originally Published by Sanofi.

Starting in June, Sanofi will further expand its innovative Insulins Valyou Savings Program so people living with diabetes in the United States can pay $99 to access their Sanofi insulins* with a valid prescription, for up to 10 boxes of pens and/or 10 mL vials per month. The expansion of this program helps to address the challenge too many patients face regarding unpredictable and unaffordable pricing for their insulin.

“It is unacceptable to Sanofi that some people living with diabetes are struggling to pay for their insulin, so we have moved to act creatively and aggressively to help address affordability and access needs,” said Michelle Carnahan, Head of North America Primary Care at Sanofi. “By giving those who require both long-acting and/or mealtime insulins or use more than one box of pens or one vial per month access to their insulins for one flat price, we aim to help limit the burden on the individuals who have high out-of-pocket costs at the pharmacy counter.”

People exposed to high out-of-pocket prices at the pharmacy counter can participate in the Insulins Valyou Savings Program regardless of income level. This includes those who are paying high retail prices for their insulin and those who don’t qualify for other patient assistance programs.

Under current government regulations, pharmaceutical companies cannot offer this type of program to patients insured under Medicare, Medicaid, or similar federal or state programs, though Sanofi supports changing rules to expand this access program to all those who might benefit.

Kelly L. Close, co-founder, The diaTribe Foundation, and president, Close Concerns, said, “Sanofi is taking this vital, transformational action to make its insulins more affordable through this program. The U.S. diabetes community is in the middle of a crisis, because our dysfunctional healthcare system doesn’t allow equal, affordable, access to insulin. As patient advocates at diaTribe, we have been strongly urging manufacturers, insurers, healthcare providers, pharmacy benefit managers – and the government – to work together to help alleviate this problem. Today, we recognize Sanofi for their outstanding leadership in order to make their insulins available at a better price for all, regardless of income or dosing needs.”

A year ago, Sanofi launched the Insulins Valyou Savings Program to enable those who pay cash to pay the set prices of $99 for one 10mL vial or $149 for a box of pens. Now, up to 10 boxes of pens and/or 10mL vials will cost $99 per month.

Since it was launched last April, the program has resulted in approximately $10 million in patient savings. The program is available at U.S. pharmacies.

“As premiums on insurance plans continue to climb, some people living with diabetes have had to exit the higher premiums so they can find ways to pay less. The result may be the loss of prescription benefits,” said Lon Chenowith, who has been living with diabetes for more than 30 years. “That was what I was forced to do last year. Sanofi has savings programs for people who have been prescribed their insulin that can help them save on prescription costs. They have been a big encouragement to people like me.”

For more information or to learn how to access this program, visit www.InsulinsValYOU.com.

Additional patient resources available for accessing Sanofi medicines

Sanofi continues to offer other resources to make insulins more accessible including co-pay cards which may limit out-of-pocket expenses sometimes to $0 for all commercially insured patients regardless of income level. In addition, Sanofi offers assistance programs that provide medications, including insulin, at no charge for qualified low-income, uninsured patients through the patient assistance component of the Sanofi Patient Connection program. Together, these programs demonstrate the company’s dedication to finding support to help people living with diabetes gain access to the insulins they need.

Sanofi also encourages anyone who is prescribed a Sanofi medicine who may be having financial challenges or trouble navigating their insurance, to call Sanofi Patient Connection at (888) 847-4877 where eligible patients can be connected to the medicines and resources they need at no cost.

* The Insulins Valyou Savings Program does not include Sanofi’s combination insulin product.

Latest News

KPMG on the Net-Zero Readiness of the United States

Originally published at info.kpmg.us. KPMG ranked No. 16 on The DiversityInc Top 50 Companies for Diversity list in 2021.   From board rooms to the halls of country capitals, leaders across the public and private sectors are increasingly deploying strategies to address climate change and drive towards a future net-zero…

Georgia Power

Georgia Power Partners With Nonprofit ‘Voices for Georgia’ To Promote Literacy for Pre-K Students

Originally published at southerncompany.com. Southern Company ranked No. 20 on The DiversityInc Top 50 Companies for Diversity list in 2021.   Georgia Power has partnered with the nonprofit organization Voices for Georgia’s Children for the eighth consecutive year to celebrate Pre-K Week across the state. Like 2020, this year will be…

Southern Company Publishes Its 2019–2020 Corporate Responsibility Report

Originally published at southerncompany.com. Southern Company ranked No. 20 on The DiversityInc Top 50 Companies for Diversity list in 2021.   On Sept. 27, Souther Company released its 2019/2020 Corporate Responsibility Executive Summary, highlighting key areas of interest to help stakeholders access environmental, social and governance (ESG) disclosures and other…

Wells Fargo Appoints Vanessa Rodriguez To Lead Community Lending and Investment Within the Corporate and Investment Bank

Originally published at newsroom.wf.com. Wells Fargo ranked No. 25 on The DiversityInc Top 50 Companies for Diversity list in 2021.   On Oct. 15, Wells Fargo & Company’s (NYSE: WFC) Corporate & Investment Bank (CIB) announced that it has appointed Vanessa Rodriguez to lead Community Lending and Investment (CLI) within…

Johnson & Johnson’s Jennifer Taubert Recognized on Fortune’s Most Powerful Women in Business List

Originally published at jnj.com. Johnson & Johnson is a DiversityInc Hall of Fame company.   Jennifer Taubert, Executive Vice President and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson, has been named to Fortune‘s 2021 list of the Most Powerful Women in Business for the sixth consecutive year. Criteria for inclusion on the list include…